Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
8 pending office actions • 7 clients • 8 examiners • 6 art units • 0 of 8 (0%) have an AI response strategy ready
ProPat, LLC reports 7 pending office actions in Biotechnology & Pharmaceuticals and 535 career applications. The current unresolved workload is limited in relation to the application record included.
Its resolved allowance rate is 75.25%, with an average of 5.69 office actions per allowance. The profile combines a reported outcome rate with a comparatively involved prosecution path for allowed matters. Practitioners may view these measures as complementary indicators of results and response activity.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 2 (25%) |
| Multi-statute (no §101) | 5 (62%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHOI, WOO H | 1 | 83.7% | -4.4% |
| BECKHARDT, LYNDSEY MARIE | 1 | 27.8% | +48.0% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
| EDMONDSON, LYNNE RENEE | 1 | 71.4% | +15.9% |
| CABRAL, ROBERT S | 1 | 62.8% | +32.3% |
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
| SMOOT, MORIAH SIMONE MCMIL | 1 | 64.2% | +7.5% |
| YU, HONG | 1 | 31.1% | +5.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260775 | Labeling precursors and radiotracers for nuclear medicine diagnosis and therapy of prostate cancer-induced bone metastases | CABRAL, ROBERT S | 46d overdue |
| 16625401 | SELF-REMINDING PATCH | YU, HONG | 30d overdue |
| 17278844 | TRANSDERMAL THERAPEUTICS SYSTEM WITH BARRIER LAYER | KETCHAM, KAREN A | 8d |
| 18858798 | Racetrack Memory Reading Device based on Josephson Diode Effect | CHOI, WOO H | — |
| 18844998 | LASER-APPLIED MARKINGS FOR MEDICAL DEVICES FOR IMPROVED SONOGRAPHIC AND RADIOLOGICAL IMAGING | BECKHARDT, LYNDSEY MARIE | — |
| 18479190 | MAGNETIC, FUNCTIONALIZED POLYMER SUBSTRATES FOR RADIOFREQUENCY APPLICATIONS | EDMONDSON, LYNNE RENEE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260775 | Labeling precursors and radiotracers for nuclear medicine diagnosis and therapy of prostate cancer-induced bone metastases | CABRAL, ROBERT S | 46d overdue |
| 17278844 | TRANSDERMAL THERAPEUTICS SYSTEM WITH BARRIER LAYER | KETCHAM, KAREN A | 8d |
| 18844998 | LASER-APPLIED MARKINGS FOR MEDICAL DEVICES FOR IMPROVED SONOGRAPHIC AND RADIOLOGICAL IMAGING | BECKHARDT, LYNDSEY MARIE | — |
| 18721573 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | JONES, DAMERON LEVEST | — |
| 18479190 | MAGNETIC, FUNCTIONALIZED POLYMER SUBSTRATES FOR RADIOFREQUENCY APPLICATIONS | EDMONDSON, LYNNE RENEE | — |
| Art Unit | Apps |
|---|---|
| 1614 | 3 |
| 3992 | 1 |
| 1613 | 1 |
| 1618 | 1 |
| 1734 | 1 |
| 1733 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18858798 | Racetrack Memory Reading Device based on Josephson Diode Effect | MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. | CHOI, WOO H | 3992 | §102§103§112 | Non-Final OA | — | Pending | Oct 22, 2024 |
| 18844998 | LASER-APPLIED MARKINGS FOR MEDICAL DEVICES FOR IMPROVED SONOGRAPHIC AND RADIOLOGICAL IMAGING | Thüringisches Institute Für Textile- Und Kunstostoff-Forschung E.V. | BECKHARDT, LYNDSEY MARIE | 1613 | §103§112 | Non-Final OA | — | Pending | Sep 09, 2024 |
| 18721573 | FAP-TARGETING PHARMACEUTICAL PRODUCT FOR THERAPY AND DIAGNOSIS OF CANCERS | Atoms For Cure GmbH | JONES, DAMERON LEVEST | 1618 | §112 | Non-Final OA | — | Pending | Jun 18, 2024 |
| 18479190 | MAGNETIC, FUNCTIONALIZED POLYMER SUBSTRATES FOR RADIOFREQUENCY APPLICATIONS | Thueringisches Institute Fuer Textile- Und Kunstostoff-Forschung E.V. | EDMONDSON, LYNNE RENEE | 1734 | §103§112 | Non-Final OA | — | Pending | Oct 02, 2023 |
| 18260775 | Labeling precursors and radiotracers for nuclear medicine diagnosis and therapy of prostate cancer-induced bone metastases | Scv-Spezialchemikalienvertrieb GmbH | CABRAL, ROBERT S | 1614 | §102§103Other | Non-Final OA | 46d overdue | Pending | Jul 07, 2023 |
| 17278844 | TRANSDERMAL THERAPEUTICS SYSTEM WITH BARRIER LAYER | LTS LOHMANN THERAPIE-SYSTEME AG | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | 8d | Pending | Mar 23, 2021 |
| 16961010 | Device for supporting and guiding a flow for metallic workpieces, and method for thermochemical treatment | Ald Vacuum Technologies GmbH | SMOOT, MORIAH SIMONE MCMIL | 1733 | §112 | Non-Final OA | 13d | Pending | Jul 09, 2020 |
| 16625401 | SELF-REMINDING PATCH | LTS LOHMANN THERAPIE-SYSTEME AG | YU, HONG | 1614 | §103§112 | Non-Final OA | 30d overdue | Pending | Dec 20, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial75.2% of resolved applications prosecuted by Propat, LLC were allowed, across 535 applications in USPTO records.
5.69 office actions per allowed application on average.
8 pending office actions as of October 2026, for 7 clients, before 8 examiners in 6 art units.
